Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia

Kaori Ikeda, Fumika Mano‐Usui, Yo Kishimoto, Daisuke Yabe, Nobuya Inagaki, Koichi Omori, Yoji Nagai

Open source

DOI
10.1111/dom.16221
Published
2025-02-03
Container
Diabetes, Obesity and Metabolism
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/dom.16221,
  title = {Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia},
  author = {Kaori Ikeda and Fumika Mano‐Usui and Yo Kishimoto and Daisuke Yabe and Nobuya Inagaki and Koichi Omori and Yoji Nagai},
  year = {2025},
  journal = {Diabetes, Obesity and Metabolism},
  doi = {10.1111/dom.16221},
  url = {https://doi.org/10.1111/dom.16221}
}

RIS

TY  - JOUR
TI  - Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia
AU  - Kaori Ikeda
AU  - Fumika Mano‐Usui
AU  - Yo Kishimoto
AU  - Daisuke Yabe
AU  - Nobuya Inagaki
AU  - Koichi Omori
AU  - Yoji Nagai
PY  - 2025
JO  - Diabetes, Obesity and Metabolism
DO  - 10.1111/dom.16221
UR  - https://doi.org/10.1111/dom.16221
ER  - 

APA

Ikeda, K., Mano‐Usui, F., Kishimoto, Y., Yabe, D., Inagaki, N., Omori, K., & Nagai, Y. (2025). Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16221

Source records